Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has just gotten the green light from the U.S. Food and Drug Administration (FDA) for a new medicine called Verapamil Hydrochloride Extended-Release Tablets. These tablets help people lower their high blood pressure. Lowering high blood pressure is important because it can significantly reduce the risk of serious health problems like strokes and heart attacks.

Key Points

• Zydus received FDA approval for Verapamil Hydrochloride tablets.
• Tablets lower blood pressure, reducing stroke and heart attack risk.
• Dosages available: 120mg, 180mg, and 240mg.
• Production will occur in Baddi, Himachal Pradesh, India.
• U.S. sales reached $24.5 million in the last year (IQVIA).
• This approval expands Zydus’ portfolio of cardiovascular medications.

These tablets are available in three different strengths: 120 mg, 180 mg, and 240 mg. Zydus will be making these tablets at their factory in Baddi, Himachal Pradesh, India.

Sales of these tablets in the United States reached approximately $24.5 million during the period of September 2025, according to data from IQVIA. This demonstrates the current market demand for this type of medication.

This approval represents a strategic advancement for Zydus Lifesciences within the cardiovascular therapeutic area.